Overview Patiromer for Treatment of Hyperkalaemia in Children From Birth to <6 Years of Age Status: Not yet recruiting Trial end date: 2025-09-30 Target enrollment: Participant gender: Summary A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 6 years of age with hyperkalaemia Phase: Phase 2 Details Lead Sponsor: Vifor Pharma, Inc.